Lhasa Limited shared knowledge shared progress
Publications

2. Risk assessment of potential mutagenic impurities in anti-hypertensive drug products approved in Brazil - Fernanda Waechter (Video)

Waechter F;

This presentation was given by Lhasa Limited, Principal Application Scientist, Fernanda Waechter, as part of the webinar 'An industry perspective on the qualification of impurities and degradation products to meet RDC 53, ICH M7, Q3A and Q3B guidelines.'

This publication is a video of the slides presented. 

Download

Additional Documents

    © 2023 Lhasa Limited | Registered office: Granary Wharf House, 2 Canal Wharf, Leeds, LS11 5PS, UK Tel: +44 (0)113 394 6020
    VAT number 396 8737 77 | Lhasa Limited is registered as a charity (290866)| Company Registration Number 01765239 (England and Wales).